US2012309678A1PendingUtilityA1

Treatment of Inflammatory Bowel Diseases With Mammal Beta Defensins

54
Assignee: KJAER TANJA MARIA ROSENKILDEPriority: Jul 18, 2008Filed: Jul 9, 2012Published: Dec 6, 2012
Est. expiryJul 18, 2028(~2 yrs left)· nominal 20-yr term from priority
Inventors:Tanja Maria Rosenkilde KjaerThomas KrusePer Holse MygindKaroline Sidelmann BrinchSoeren KjaerulffBirgitte Andersen
A61P 43/00A61P 31/04A61P 29/00A61P 1/00A61K 38/1729C07K 14/4723A61P 1/04A61K 38/17A61K 38/16
54
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to treatment of inflammatory bowel diseases with mammal beta defensins.

Claims

exact text as granted — not AI-modified
1 . A method of treating an inflammatory bowel disease, comprising administering to a subject in need of such treatment an effective amount of a beta-defensin comprising an amino acid sequence that has at least 85% identity to the amino acid sequence of SEQ ID NO: 5. 
     
     
         2 . The method of  claim 1 , wherein the effective amount is effective to reduce TNF-alpha activity in the treated tissue. 
     
     
         3 . The method of  claim 1 , wherein the beta-defensin is administered orally. 
     
     
         4 . The method of  claim 1 , wherein the beta-defensin is administered parenterally. 
     
     
         5 . The method of  claim 4 , wherein the beta-defensin is administered subcutaneously or intravenously. 
     
     
         6 . The method of  claim 1 , wherein the beta-defensin is administered at a daily dosage of from about 0.001 mg/kg body weight to about 10 mg/kg body weight. 
     
     
         7 . The method of  claim 1 , wherein the beta-defensin is administered at a daily dosage of from about 0.01 mg/kg body weight to about 10 mg/kg body weight. 
     
     
         8 . The method of  claim 1 , wherein the beta-defensin comprises the amino acid sequence of SEQ ID NO: 5. 
     
     
         9 . The method of  claim 1 , wherein the beta-defensin consists of the amino acid sequence of SEQ ID NO: 5. 
     
     
         10 . The method of  claim 1 , wherein the beta-defensin comprises conserved cysteine residues corresponding to amino acid positions 8, 15, 20, 30, 37, 38 of SEQ ID NO: 5. 
     
     
         11 . The method of  claim 1 , wherein any amino acid substitution in the beta-defensin relative to SEQ ID NO: 5 is a conservative substitution. 
     
     
         12 . A method of treating an inflammatory bowel disease, comprising administering parenterally to a subject in need of such treatment an effective amount of a beta-defensin comprising the amino acid sequence of SEQ ID NO: 5.

Join the waitlist — get patent alerts

Track US2012309678A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.